Hyposmia as a marker of (non-)motor disease severity in Parkinson’s disease

Dareia S. Roos1 · Jos W. R. Twisk2 · Pieter G. H. M. Raijmakers3 · Richard L. Doty4 · Henk W. Berendse1

Received: 1 July 2019 / Accepted: 31 August 2019 / Published online: 12 September 2019
© The Author(s) 2019

Abstract
The aim of this study was to evaluate the relationship of hyposmia in Parkinson’s disease (PD) with other motor and non-motor symptoms and with the degree of nigrostriatal dopaminergic cell loss. A total of 295 patients with a diagnosis of PD were included. Olfactory function was measured using the University of Pennsylvania Smell Identification Test (UPSIT). Motor symptoms were rated using the Unified Parkinson’s Disease Rating Scale motor subscale (UPDRS III). To evaluate other non-motor symptoms, we used the Mini-Mental State Examination (MMSE) as a measure of global cognitive function and validated questionnaires to assess sleep disturbances, psychiatric symptoms, and autonomic dysfunction. A linear regression model was used to calculate correlation coefficients between UPSIT score and motor and non-motor variables [for psychiatric symptoms a Poisson regression was performed]. In a subgroup of patients (n = 155) with a dopamine transporter (DaT) SPECT scan, a similar statistical analysis was performed, now including striatal DaT binding. In the regression models with correction for age, sex, disease duration, and multiple testing, all motor and non-motor symptoms were associated with UPSIT scores. In the subgroup of patients with a DaT-SPECT scan, there was a strong association between olfactory test scores and DaT binding in both putamen and caudate nucleus. Hyposmia in PD is associated with various motor and non-motor symptoms, like cognition, depression, anxiety, autonomic dysfunction and sleep disturbances, and with the degree of nigrostriatal dopaminergic cell loss. This finding adds further confirmation that hyposmia holds significant promise as a marker of disease progression.

Keywords Parkinson’s disease · Olfaction · Disease severity · Motor symptoms · Non-motor symptoms

Introduction
Hyposmia is one of the most common non-motor symptoms in Parkinson’s disease (PD), with a reported prevalence of up to 90% (Doty et al. 1988; Haehner et al. 2009; Hawkes et al. 1997), that may precede the first motor symptoms by several years (Ponsen et al. 2004; Ross et al. 2008). Given the increasing load of Lewy body pathology in the olfactory system with advancing neuropathological stages of PD (Braak et al. 2003; Del Tredici et al. 2002), one would expect a progressive decline in olfactory function that correlates with other clinical markers of disease progression. However, previous clinical studies have yielded conflicting data. Although some studies showed a correlation between disease duration and olfactory function (Deeb et al. 2010; Ramjith et al. 2010), most studies have failed to find this correlation (Cavaco et al. 2015; Haehner et al. 2009; Hawkes et al. 1997; Herting et al. 2008; Lee et al. 2015; Masala et al. 2018). In the only longitudinal study, olfactory loss in PD remained stable over time (Doty et al. 1988). Similarly, while in some studies hyposmia was associated with disease severity as measured with the Unified PD Rating Scale motor subscale (UPDRS III) (Cavaco et al. 2015; Deeb et al. 2010; Lee et al. 2015; Masala et al. 2018; Tissington et al. 2017), others had conflicting results (Ponsen et al. 2004; Ross et al. 2008). In this study, we aimed to evaluate the relationship of hyposmia with disease severity as measured by the Unified PD Rating Scale motor subscale (UPDRS III) and the Mini-Mental State Examination (MMSE) as a measure of global cognitive function, and with other non-motor symptoms, such as sleep disturbances, psychiatric symptoms, and autonomic dysfunction.
et al. 2001), others found no association between the degree of hyposmia and disease stage or severity (Boesveldt et al. 2008; Doty et al. 1988; Haehner et al. 2009; Herting et al. 2008; Ramjit et al. 2010; Siderowf et al. 2005).

So far, only few studies have focused on the relationship between olfactory function and non-motor symptoms in PD. Correlations have been reported between hyposmia and apathy (Cramer et al. 2010; Hong et al. 2015), cognitive dysfunction (Dommelof et al. 2017; Fullard et al. 2016), and autonomic failure (Chen et al. 2015; Fullard et al. 2016; Goldstein et al. 2010). In a few studies in which striatal dopamine transporter (DaT) binding was used as a marker of the nigrostriatal dopaminergic deficit, hyposmia was associated with lower striatal DaT binding (Bohnen et al. 2007; Siderowf et al. 2005).

The aim of this study was to examine the association between olfactory function and various motor and non-motor symptoms and striatal DaT binding in a large cohort of PD patients.

Methods
Study population

For this study, we used the clinical and dopamine transporter imaging data of 295 PD patients collected as part of their routine clinical care during visits to the outpatient clinic for movement disorders at the VU University Medical Center (VUmc). All patients were seen between May 2008 and February 2014 by a neurologist specialized in movement disorders and fulfilled the clinical diagnostic criteria of the UK PD Society Brain Bank. Olfactory testing using the University of Pennsylvania Smell Identification Test (UPSIT) has been routinely performed in all-new referred patients seen at the outpatient clinic. We selected those with a complete UPSIT and a diagnosis of PD. The mean age of our patients was 65.3 years, with a mean disease duration of 5.3 years (Table 1).

Disease duration was measured from the onset of subjective motor symptoms. When a patient had experienced motor symptoms for a period between 6 and 12 months, disease duration was defined as 1 year; in case of a duration of subjective motor symptoms shorter than 6 months, disease duration was defined as zero years. Disease stage was defined using the modified Hoehn & Yahr staging [H&Y (Goetz et al. 2004)]. The majority of patients were in stages 2 and 2.5. Most patients used levodopa monotherapy, a dopamine agonist or a combination of levodopa and a dopamine agonist. In a subgroup of 155 patients, a DaT Single-Photon Emission Computed Tomography (DaT-SPECT) scan was available. The mean age of this subgroup was 65.4 years, with a mean disease duration of 3.7 years (Table 1). All patients had provided written informed consent to store the clinical and imaging data obtained as part of their routine clinical care in a database to be used later for scientific research.

Table 1 Characteristics of the study population

| Description                 | All participants | PD patients (n = 295) | PD patients with DaT-SPECT (n = 155) |
|-----------------------------|------------------|-----------------------|-------------------------------------|
| Mean age, years             | 65.3 (10.4)      | 65.4 (10.7)           |
| Males n (%)                 | 179 (60.7%)      | 95 (61.3%)            |
| Mean disease duration, years| 5.3 (4.9)        | 3.7 (3.7)             |
| Modified H & Y stage, n (%) |                  |                      |
| 1                           | 31 (10.5%)       | 19 (12.3%)            |
| 1.5                         | 21 (7.1%)        | 13 (8.4%)             |
| 2                           | 118 (40.0%)      | 69 (44.5%)            |
| 2.5                         | 65 (22.0%)       | 32 (20.6%)            |
| 3                           | 35 (11.9%)       | 16 (10.3%)            |
| 4                           | 15 (5.1%)        | 3 (1.9%)              |
| 5                           | 10 (3.4%)        | 3 (1.9%)              |
| UPSIT                       | 20 ± 7.3         | 21.2 ± 7.2            |
| UPDRS III                   | 27.3 ± 13.6 (n = 288) | 25.2 ± 12.4 (n = 153) |
| MMSE                        | 27.3 ± 3.3 (n = 280) | 27.6 ± 3.3 (n = 148)  |
| SCOPA-SLEEP                 | 23.4 ± 7.8 (n = 286) | 22.3 ± 6.7 (n = 150)  |
| SCOPA-PC                    | 1.1 ± 1.5 (n = 272) | 0.9 ± 1.2 (n = 147)   |
| SCOPA-AUT                   | 35.6 ± 8.7 (n = 281) | 34.6 ± 8.5 (n = 150)  |
| BDI                         | 11.6 ± 8.2 (n = 285) | 10.5 ± 7.6 (n = 151)  |
| BAI                         | 15.0 ± 10.0 (n = 280) | 12.7 ± 8.7 (n = 146)  |

Data are shown as numbers (%) or mean (SD)

PD Parkinson’s disease, H&Y Hoehn & Yahr, DaT-SPECT dopamine transporter single-photon emission computed tomography

Clinical profiling

The Unified Parkinson’s Disease Rating Scale motor subscale (UPDRS III; range 0–108) (Fahn and Elton 1987) was used as a measure of motor symptom severity. Motor symptom severity was rated while patients were on medication. Cognitive function was tested using the Mini-Mental State Examination (MMSE) (Folstein et al. 1975). Sleep disturbances were assessed using the SCales for Outcomes in Parkinson’s disease for sleep (SCOPA-SLEEP) (Marius et al. 2003). To evaluate psychiatric symptoms, the SCales for Outcomes in PArkinson’s disease Psychiatric Complications (SCOPA-PC) (Visser et al. 2007) was used. Autonomic failure was assessed by means of the Scales for Outcomes in PArkinson’s disease Autonomic dysfunction (SCOPA-AUT) (Visser et al. 2004). The questions in the SCOPA-AUT aimed at sexual functioning were excluded from our analysis, as too many data were missing. Depressive symptoms and anxiety symptoms were screened with...
the Beck Depression Inventory (BDI) (Beck et al. 1961) and the Beck Anxiety Inventory (BAI) (Beck et al. 1988), respectively. For all tests except the MMSE, a higher score means more severe symptoms. Tests were either self-administered (SCOPA-SLEEP, SCOPA-AUT, BDI and BAI), or administered by a trained physician or nurse specialist (UPDRS III, modified H&Y, MMSE, SCOPA-PC) in the same period as the UPSIT was performed.

**Olfactory testing**

The Dutch version of the UPSIT was used as a measure of olfactory function (Doty et al. 1984). The UPSIT is a self-administered forced-choice odour identification test consisting of 40 odorized items. After scratching a patch containing microcapsules filled with odorant, the subject sniffs the released odorant and chooses the best alternative from four response alternatives. The test was self-administered at home. Completeness was checked in the hospital, and when necessary the patient was asked to complete any missing items. The total score was calculated by adding up all correct answers.

**Nuclear imaging: DaT-SPECT**

\[ ^{123}I \text{-} N\text{-}ω\text{-}fluoropropyl-2β\text{-}carbomethoxy-3β\text{-}(4\text{-}iododophenyl)nortropane (}\text{[}^{123}\text{I}\text{]FP-CIT}) \text{ SPECT was used to measure dopamine transporter (DaT) binding. To block uptake of free radioactive iodide in the thyroid, all patients received potassium perchlorate orally.}\text{[}^{123}\text{I}\text{]FP-CIT was injected intravenously at an approximate dose of 185 MBq (specific activity > 185 MBq/hmol; radiochemical purity > 99%). Three hours after injection, the images were acquired. Slices were made over 300-s periods, during which the head of the patient was positioned in the camera. Semi-quantitative analysis using a standard template with regions of interest (ROI) was used for analysing the SPECT images. Tracer binding values in the individual regions were used to calculate a tracer binding ratio of DaT binding in the putamen or caudate nucleus and the occipital cortex, which was used as a reference area. The least and most affected side of the putamen and the caudate nucleus were used in the statistical analysis.**

**Statistical analysis**

To verify whether the percentage of patients with an olfactory deficit was comparable to that known from the literature, we calculated this percentage using previously established optimal discrimination criteria for the UPSIT (Doty et al. 1995). These criteria are adjusted for age and gender. To analyse the relationship between olfactory function and each of the motor and non-motor variables, a linear regression analysis was used. For each variable, three analyses were performed: the first crude, the second adjusted for age and gender, and the third further adjusted for disease duration. Data from the SCOPA-SLEEP and BDI were first log transformed, because of non-normally distributed residuals. To analyse the SCOPA-PC a Poisson regression was performed. In the group of patients with an available DaT-SPECT scan, the same three analyses were performed with UPSIT, UPDRS III and MMSE as dependent variables. The data were analyzed with SPSS 22.0 (SPSS Inc., Chicago, IL, USA). The significance level was set at 0.05 and to adjust for multiple testing a Bonferroni correction was applied.

**Results**

**Correlations with clinical measures of motor and non-motor function**

In our total group of 295 PD patients, 82.7% were hyposmic or anosmic when compared to the optimal discrimination criteria established by Doty et al. (1995). Motor function as measured with UPDRS III was significantly associated with olfaction, also in the models in which we adjusted for sex and age (Table 2; Fig. 1). For each of the non-motor symptoms we assessed, test scores were significantly associated with UPSIT scores. The strongest crude association of olfactory function was with SCOPA-AUT scores (Fig. 2). As expected, adjustment for age and sex attenuated all observed associations, although all associations remained statistically significant, except for the correlation with MMSE. Further adjustment for disease duration did not influence the regression coefficients, besides correlation with MMSE and UPDRS III, which indicates that the influence of disease duration is negligible.

**Correlations with striatal DaT binding**

In the subgroup of patients for whom DaT-SPECT data were available, the prevalence of olfactory dysfunction (i.e., hyposmia or anosmia) was 80%, which was comparable to the prevalence in the total group. The association between UPSIT score and striatal DaT binding in all selected regions was moderate, even after adding sex, age, and disease duration in the analysis, except for the most affected side of the caudate when adding disease duration in the model (Table 3, Fig. 3). Motor function was only weakly associated with striatal binding in all four ROI’s, with the strongest relation between UPDRS III and the least affected side of the putamen. After adjustment for sex, age, and disease duration (models 2 and 3), the association between UPDRS III score and DaT binding was no longer significant in most of the four striatal regions, except in the least affected side of
Table 2  Results of the linear regression analyses relating UPSIT score to various motor and non-motor variables

|                      | Model 1             | Model 2             | Model 3             | p          |
|----------------------|---------------------|---------------------|---------------------|------------|
| **UPDRS III**        |                     |                     |                     |            |
| Model 1              | $-0.254$            | $-0.466$            | $-0.673$            | $<0.001^*$ |
| Model 2              | $-0.157$            | $-0.289$            | $-0.499$            | 0.007*     |
| Model 3              | $-0.129$            | $-0.237$            | $-0.442$            | 0.023      |
| **MMSE**             |                     |                     |                     |            |
| Model 1              | 0.208               | 0.093               | 0.041; 0.145        | $<0.001^*$ |
| Model 2              | 0.143               | 0.064               | 0.010; 0.118        | 0.020      |
| Model 3              | 0.122               | 0.055               | 0.001; 0.109        | 0.045      |
| **SCOPA-SLEEP**a     |                     |                     |                     |            |
| Model 1              | $-0.185$            | $-0.003$            | $-0.006$            | 0.002*     |
| Model 2              | $-0.197$            | $-0.004$            | $-0.006$            | 0.002*     |
| Model 3              | $-0.163$            | $-0.003$            | $-0.005$            | 0.007*     |
| **SCOPA-PC**         |                     |                     |                     |            |
| Model 1              | 0.949$^b$           | (0.934; 0.965)      | $<0.001^*$          |            |
| Model 2              | 0.950$^b$           | (0.934; 0.966)      | $<0.001^*$          |            |
| Model 3              | 0.953$^b$           | (0.937; 0.969)      | $<0.001^*$          |            |
| **SCOPA-AUT**        |                     |                     |                     |            |
| Model 1              | $-0.318$            | $-0.376$            | $-0.508$            | $<0.001^*$ |
| Model 2              | $-0.249$            | $-0.294$            | $-0.431$            | $<0.001^*$ |
| Model 3              | $-0.204$            | $-0.241$            | $-0.366$            | $<0.001^*$ |
| **BDI**$^c$          |                     |                     |                     |            |
| Model 1              | $-0.203$            | $-0.203$            | $-0.015$            | 0.001*     |
| Model 2              | $-0.190$            | $-0.099$            | $-0.015$            | 0.002*     |
| Model 3              | $-0.168$            | $-0.008$            | $-0.014$            | 0.006*     |
| **BAI**              |                     |                     |                     |            |
| Model 1              | $-0.203$            | $-0.276$            | $-0.434$            | 0.001*     |
| Model 2              | $-0.208$            | $-0.283$            | $-0.447$            | 0.001*     |
| Model 3              | $-0.175$            | $-0.238$            | $-0.395$            | 0.003*     |

$B =$ standardized coefficient. $B =$ unstandardized coefficient. Model 1 for UPSIT only. Model 2: adjusted for sex and age. Model 3: as model 2 with adjustment for disease duration

**UPSIT** University of Pennsylvania Smell Identification Test, **UPDRS III** Unified Parkinson’s Disease Rating Scale motor subscale, **MMSE** Mini-Mental State Examination, **SCOPA** Scales for Outcomes in Parkinson’s Disease, **PC** psychiatric complications, **AUT** autonomic dysfunction, **BDI** Beck Depression Inventory, **BAI** Beck Anxiety Inventory

*a* Log transformed data

*b* Exp(B) with Poisson regression

*c* Significant with Bonferroni correction ($p = 0.00714$)

---

Fig. 1  Scatter plot illustrating the correlation between UPSIT scores and UPDRS III motor scores

Fig. 2  Scatter plot illustrating the correlation between UPSIT scores and SCOPA-Autonomic dysfunction scores
the putamen with the second model. Cognitive function, as measured by the MMSE, had a moderate association with striatal DaT binding in both putamen and caudate nucleus, also in the model adjusted for sex, age, and in all ROI’s except the least affected side of putamen, with disease duration.

**Discussion**

The present cross-sectional study demonstrates that olfactory function, as measured by the UPSIT, correlates with various motor and non-motor measures of disease severity in PD patients. Especially, the relationship with sleep, depression and anxiety has not been reported previously. This observation emphasizes the profound involvement of the olfactory system in the PD process. In addition, greater olfactory dysfunction was associated with more pronounced loss of nigrostriatal dopamine neurons, as measured by DaT-SPECT, in both the putamen and caudate nucleus. Finally, the data confirm the previously reported high prevalence of olfactory loss in PD patients as measured by the UPSIT (Berendse et al. 2011; Deeb et al. 2010; Doty et al. 1988; Hawkes and Shephard 1998; Hawkes et al. 1997).

It is important to note that the poorest olfactory function was associated with a higher UPDRS III score, corresponding to more severe motor symptoms, even when correcting for sex and age. Only when using a conservative adjustment

---

**Table 3** Results of the linear regression analyses relating DaT binding in the putamen to measures of olfactory, motor, and cognitive function

| Measure | Most affected side putamen | | Least affected side putamen | | |
|---------|---------------------------|--------------------------------|---------------------------|--------------------------------|
|         | B (95% CI)                | p                             | B (95% CI)                | p                             |
| UPSIT   |                           |                               |                           |                               |
| Model 1 | 0.331 (4.160; 11.108)     | <0.001*                       | 0.304 (2.764; 8.309)      | <0.001*                       |
| Model 2 | 0.258 (2.453; 9.461)      | 0.001*                        | 0.224 (1.264; 6.909)      | 0.005*                        |
| Model 3 | 0.253 (2.176; 9.516)      | 0.002*                        | 0.217 (0.968; 6.930)      | 0.010*                        |
| UPDRS III | -0.266 (16.697; -4.411) | 0.001*                        | -0.291 (-13.925; -4.286) | <0.001*                       |
| Model 2 | -0.187 (13.549; -1.254)  | 0.019                         | -0.208 (-11.378; -1.630) | 0.009*                        |
| Model 3 | -0.115 (10.785; 1.685)   | 0.151                         | -0.131 (-9.110; 0.880)   | 0.106                         |
| MMSE    |                           |                               |                           |                               |
| Model 1 | 0.322 (1.730; 4.944)     | <0.001*                       | 0.289 (1.087; 3.655)      | <0.001*                       |
| Model 2 | 0.283 (1.287; 4.578)     | 0.001*                        | 0.242 (0.652; 3.308)     | 0.004*                        |
| Model 3 | 0.250 (0.883; 4.301)     | 0.003*                        | 0.203 (0.269; 3.052)     | 0.020                         |

---

Model 1: correlation between variable and DaT-SPECT caudate nucleus most affected side (left) and least affected side (right). Model 2: adjusted for age and sex. Model 3: as model 2 plus adjustment with disease duration

*Significant with Bonferroni correction (p = 0.0166)
for multiple testing (Bonferroni), the correlation lost statistical significance. Also previous studies have noted an association between UPDRS III scores and scores on the UPSIT (Berendse et al. 2011; Deeb et al. 2010) and various other olfactory tests (Cavaco et al. 2015; Lee et al. 2015; Masala et al. 2018; Tissingh et al. 2001). The reason why previous studies failed to find an association between olfactory dysfunction and disease severity may reflect differences in study populations, sample sizes, or the types of olfactory tests that were employed (Boesveldt et al. 2008; Doty et al. 1988; Haehner et al. 2009; Herting et al. 2008; Ramjit et al. 2010). A contributory factor is the relative weakness of the association, making it more difficult to detect in studies with insufficient power.

Our finding that disease duration is not independently associated with the degree of olfactory dysfunction is in accord with the findings of earlier studies (Cavaco et al. 2015; Doty et al. 1988; Haehner et al. 2009; Hawkes and Shephard 1998; Herting et al. 2008; Lee et al. 2015; Masala et al. 2018). Thus, olfactory function in PD is largely impacted by disease severity and clinical phenotype, but not by disease duration.

Lower olfactory test scores were correlated in our study with decreased global cognitive function, as measured by the MMSE. This is in line with the results of a previous study in which lower UPSIT scores were associated with more cognitive impairment, as measured by the Montreal Cognitive Assessment (MoCA) test (Fullard et al. 2016). In this study, baseline olfactory test scores were associated with a decline in verbal memory and executive function at follow-up and predicted, in combination with lower Aβ1–42 levels, the development of mild cognitive impairment (MCI) within three years. In another study, lower baseline scores on the Brief Smell Identification Test (B-SIT; a test made up of 12 UPSIT items) increased the risk of dementia up to 10 years after PD diagnosis, independent of baseline cognitive performance (Domellof et al. 2017).

The present observation that the severity of the olfactory deficit in PD is associated with the degree of autonomic failure confirms the results of two previous clinical studies in which the olfactory deficit correlated with a higher score on the SCOPA-AUT (Chen et al. 2015; Fullard et al. 2016). In addition, Goldstein et al. reported an association between olfactory test scores and physiological, neurochemical, and neuroimaging markers of autonomic failure in PD (Goldstein et al. 2010). In the present study a higher score on the SCOPA-SLEEP, corresponding to more severe sleeping problems, was associated with a lower UPSIT score. As far as we know, this is the first study to investigate the direct relation between UPSIT scores and sleeping disturbances in PD. However, REM-sleep behaviour disorder has been related to a decline in such scores (Miyamoto et al. 2009; Postuma et al. 2009; Shin et al. 2013; Stiasny-Kolster et al. 2005).

Neuropsychiatric symptoms are highly prevalent in PD (Weintraub and Burn 2011). In a large cross-sectional study by Morley et al., PD patients with lower UPSIT scores exhibited more psychotic symptoms than those with higher UPSIT scores (Morley et al. 2011). Furthermore, measures of apathy reportedly correlate with lower scores on a number of different types of olfactory tests (Cramer et al. 2010; Hong et al. 2015; Masala et al. 2018). However, our study is the first to report a correlation between odor identification test scores and measures of depression and anxiety in PD. A few previous studies have addressed this issue but failed to observe such an association (Rossi et al. 2015; Verbaan et al. 2008), possibly because they employed an olfactory test comprised of only 16 odorants (vs. the 40 of the UPSIT), which may have limited their statistical power.

Our finding of a correlation between olfactory decline and lower striatal DaT binding is in accord with earlier findings (Bohnen et al. 2007; Siderowf et al. 2005). In both studies, this association was demonstrated in PD patients whose disease duration was approximately 2–2.5 years. In our study, the average duration of disease was longer, almost 4 years, implying that the association between smell loss and decreased DaT binding in PD continues over a considerable period of time. Our observation does not necessarily imply that a causal relationship exists between dopaminergic losses and olfactory dysfunction, since numerous other neurotransmitter and neuromodulator systems, including the cholinergic system, are altered in PD (Doty 2017). Moreover, olfactory dysfunction and most other non-motor symptoms do not seem to be influenced by dopaminergic medication (Doty et al. 1988). In addition, despite the largely ipsilateral
olfactory afferent projections from the olfactory bulb to the cerebral cortex, there is no association between the side of major motor dysfunction and the side of the nose with greater olfactory dysfunction when, on rare occasion, asymmetry is present (Doty et al. 1992). Lastly, in a PET study of patients with moderately severe PD, cholinergic denervation of the limbic archicortex was more strongly related to poor UPSIT scores than nigrostriatal dopaminergic denervation (Bohnen et al. 2010).

The present study clearly demonstrates that the severity of the olfactory deficit in PD is associated with various motor and non-motor symptoms, as well as with an imaging marker of the integrity of the nigrostriatal dopaminergic system, but not with disease duration. Whether these observations reflect the presence of a group of patients with a more rapid disease progression or suggest that there are PD subtype(s) with more extensive extranigral pathology needs to be further examined in a longitudinal study. Studying olfactory function at baseline and follow-up, in parallel with measuring various motor, non-motor, and imaging markers, may well provide an answer to this longstanding question, as well as confirm the present cross-sectional observations. Olfactory function would have a number of distinct advantages as a clinical marker of disease progression. Not only because of its early-stage presence, but also since olfactory function correlates with both motor and non-motor function and is not influenced by dopaminergic therapy. Moreover, olfactory testing with the UPSIT is non-invasive. Because of its low cost and ability to be self-administered, this test has been found to be very useful in clinical practice.

The strengths of this study include its large sample size, the use of a well-validated and reliable 40-item smell test, and its assessment of the relationship of olfactory test scores of PD patients with a wide range of both motor and non-motor functions, as well as with measures of central dopaminergic function. A potential weakness of the study is that the dosage of dopamine replacement therapy was not taken into account. However, since olfactory function and other non-motor symptoms do not seem to be influenced by dopaminergic medication (Doty et al. 1988), it is unlikely that we have introduced a major bias. Although UPDRS III scores might have been higher in patients examined while not using dopamine replacement therapy, this would likely have increased, not decreased, the observed associations. Another potential weakness is that individuals with other causes of olfactory loss, including trauma or infection, were not specifically excluded from our population. However, any effect would have led to an underestimate of the actual strength of the correlations.

In conclusion, the severity of the olfactory deficit in PD is associated with both clinical (motor and non-motor) and brain imaging measures of disease severity, not with disease duration, per se. Olfactory dysfunction, therefore, merits further longitudinal assessment as a potential clinical marker of disease progression in patients with PD.

Compliance with ethical standards

Conflict of interest R.L. Doty is President of, and major shareholder in Sensonics International, the manufacturer and distributor of smell and taste tests, including the UPSIT.

Informed consent All patients had provided written informed consent to store the clinical and imaging data obtained as part of their routine clinical care in a database to be used later for scientific research.

Open Access

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561–571
Beck AT, Epstein N, Brown G, Steer RA (1988) An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 56:893–897
Berendse HW, Roos DS, Raisjmakers P, Doty RL (2011) Motor and non-motor correlates of olfactory dysfunction in Parkinson’s disease. J Neurol Sci 310:21–24. https://doi.org/10.1016/j.jns.2011.06.020
Boesveldt S, Verbaan D, Knol DL, Visser M, van Roorden SM, van Hilten JJ, Berendse HW (2008) A comparative study of odor identification and odor discrimination deficits in Parkinson’s disease. Mov Disord 23:1984–1990. https://doi.org/10.1002/mds.22155
Bohnen NI, Gedela S, Kuwabara H, Constantine GM, Mathis CA, Studenski SA, Moore RY (2007) Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson’s disease. J Neurol 254:84–90. https://doi.org/10.1007/s00415-006-0284-y
Bohnen NI, Muller ML, Kotagal V, Koepepe RA, Kilbourn MA, Albin RL, Frey KA (2010) Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson’s disease. Brain 133:1747–1754. https://doi.org/10.1093/brain/awq379
Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211
Cavaco S et al (2015) Abnormal olfaction in Parkinson’s disease is related to faster disease progression. Behav Neurol 2015:976589. https://doi.org/10.1155/2015/976589
Chen W et al (2015) Hyposmia correlates with SNCA variant and non-motor symptoms in Chinese patients with Parkinson’s disease. Parkinsonism Relat Disord 21:610–614. https://doi.org/10.1016/j.parkreldis.2015.03.021
Cramer CK, Friedman JH, Amick MM (2010) Olfaction and apathy in Parkinson’s disease. Parkinsonism Relat Disord Relat 16:124–126. https://doi.org/10.1016/j.parkreldis.2009.09.004
Deeb J, Shah M, Muhammed N, Gunasekera R, Gannon K, Findley LJ, Hawkes CH (2010) A basic smell test is as sensitive as a dopamine transporter scan: comparison of olfaction, taste and DaTSCAN in
the diagnosis of Parkinson’s disease. QJM 103:941–952. https://doi.org/10.1093/qjmed/hcq142
Del Tredici K, Rub U, De Vos RA, Bohl JH, Braak H (2002) Where does parkinson disease pathology begin in the brain? J Neuro- pathol Exp Neurol 61:413–426
Domellof ME, Lundin KF, Edstrom M, Forsgren L (2017) Olfactory dysfunction and dementia in newly diagnosed patients with Par-kinson’s disease. Parkinsonism Relat Disord 38:41–47. https://doi. org/10.1016/j.parkreldis.2017.02.017
Doty RL (2017) Olfactory dysfunction in neurodegenerative diseases: is there a common pathological substrate? Lancet Neurol 16:478– 488. https://doi.org/10.1016/S1474-4422(17)30123-0
Doty RL, Shaman P, Dann M (1984) Development of the University of Pennsylvania Smell Identification Test: a standardized microen-capsulated test of olfactory function. Physiol Behav 32:489–502
Doty RL, Deems DA, Stellar S (1995) Olfactory testing as an aid in Parkinson’s disease: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 38:1237–1244
Doty RL, Stern MB, Pfeiffer C, Gollop SM, Hurtig HI (1992) Bilat- eral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 55:138–142
Doty RL, Bromley SM, Stern MB (1995) Olfactory testing as an aid in the diagnosis of Parkinson’s disease: development of optimal discrimination criteria. Neurogenetration 4:93–97
Fahn S, Elton R (1987) UPDRS program members. Unified Parkinson’s disease rating scale recent developments in Parkinson’s disease. vol 2, pp 153–163
Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198
Fullard ME et al (2016) Olfactory impairment predicts cognitive decline in early Parkinson’s disease. Parkinsonism Relat Disord 25:45–51. https://doi.org/10.1016/j.parkreldis.2016.02.013
Goetz CG et al (2004) Movement disorder society task force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 19:1020–1028. https://doi.org/10.1002/mds.20213
Goldstein DS, Sewell L, Holmes C (2010) Association of anosmia with autonomic failure in Parkinson disease. Neurology 74:245–251. https://doi.org/10.1212/WNL.0b013e3181ca014c
Haehner A et al (2009) Prevalence of smell loss in Parkinson’s disease: a multicenter study Parkinsonism. Relat Disord 15:490– 494. https://doi.org/10.1016/j.parkreldis.2008.12.005
Hawkes CH, Shephard BC (1998) Olfactory evoked responses and identification tests in neurological disease. Ann N Y Acad Sci 855:608–615
Hawkes CH, Shephard BC, Daniel SE (1997) Olfactory dysfunction in Parkinson’s disease. J Neurol Neurosurg Psychiatry 62:436–446
Herting B, Schulze S, Reichmann H, Haehner A, Hummel T (2008) A longitudinal study of olfactory function in patients with idiopathic Parkinson’s disease. J Neurol 255:367–370. https://doi.org/10.1007/s00415-008-0665-5
Hong JY, Sunwoo MK, Ham JH, Lee JJ, Lee PH, Sohn YH (2015) Apathy and olfactory dysfunction in early Parkinson’s disease. J Mov Disord 8:21–25. https://doi.org/10.14802/jmd.14029
Lee DH et al (2015) Is normosmic Parkinson disease a unique clinical phenotype? Neurology 85:1270–1275. https://doi.org/10.1212/ WNL.0000000000003199
Marinus J, Visser M, van Hilten JJ, Lammers GJ, Stigebout AM (2003) Assessment of sleep and sleepiness in Parkinson disease. Sleep 26:1049–1054
Masala C et al (2018) Correlation among olfactory function, motors’ symptoms, cognitive impairment, apathy, and fatigue in patients with Parkinson’s disease. J Neurol. https://doi.org/10.1007/s0041 5-018-8913-9
Miyamoto T, Miyamoto M, Iwanami M, Suzuki K, Inoue Y, Hirata K (2009) Odor identification test as an indicator of idiopathic REM sleep behavior disorder. Mov Disord 24:268–273. https://doi.org/10.1002/mds.22361
Morley JF, Weintraub D, Mamikonyan E, Moberg PJ, Siderowf AD, Duda JE (2011) Olfactory dysfunction is associated with neuropsyhiatric manifestations in Parkinson’s disease. Mov Disord 26:2051–2057. https://doi.org/10.1002/mds.23792
Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters E, Berendse HW (2004) Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann Neurol 56:173–181. https://doi. org/10.1002/ana.20160
Postuma RB, Gagnon JF, Vendette M, Montplaisir JY (2009) Markers of neurodegeneration in idiopathic rapid eye movement sleep behaviour disorder and Parkinson’s disease. Brain 132:3298– 3307. https://doi.org/10.1093/brain/awp244
Ramjit AL et al (2010) The relationship between anosmia, constipation, and orthostasis and Parkinson’s disease duration: results of a pilot study. Int J Neurosci 120:67–70. https://doi.org/10.3109/00207 45090337721
Ross GW et al (2008) Association of olfactory dysfunction with risk for future Parkinson’s disease. Ann Neurol 63:167–173. https://doi. org/10.1002/ana.21291
Rossi M et al (2015) Olfactory dysfunction evaluation is not affected by comorbid depression in Parkinson’s disease. Mov Disord 30:1275–1279. https://doi.org/10.1002/mds.26276
Shin HY, Joo EY, Kim ST, Dhong HJ, Cho JW (2013) Comparison study of olfactory function and substantia nigra hyperchogenicity in idiopathic REM sleep behavior disorder Parkinson’s disease and normal control. Neurol Sci 34:935–940. https://doi.org/10.1007/s10072-012-1164-0
Siderowf A et al (2005) [99mTc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease. Neurology 64:1716–1720. https://doi.org/10.1212/01.wnl.0000161874 .5200.5d
Stiasny-Kolster K, Doerr Y, Moller JC, Hoffken H, Behr TM, Oertel WH, Mayer G (2005) Combination of ‘idiopathic’ REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 128:126–137. https://doi.org/10.1093/brain /awh322
Tississing G, Berendse HW, Bergmans P, DeWaar R, Drukarch B, Stoof JC, Wolters EC (2001) Loss of olfaction in de novo and treated Parkinson’s disease: possible implications for early diagnosis. Mov Disord 16:41–46
Verbaan D et al (2008) Is olfactory impairment in Parkinson disease related to phenotypic or genotypic characteristics? Neurology 71:1877–1882. https://doi.org/10.1212/01.wnl.0000336561.48596 .c7
Visser M, Marinus J, Stigebout AM, Van Hilten JJ (2004) Assessment of autonomic dysfunction in Parkinson’s disease: the SCOPA-AUT. Mov Disord 19:1306–1312. https://doi.org/10.1002/ mds.20153
Visser M, Verbaan D, van Rooren SM, Stigebout AM, Marinus J, van Hilten JJ (2007) Assessment of psychiatric complications in Parkinson’s disease: the SCOPA-PC. Mov Disord 22:2221–2228. https://doi.org/10.1002/mds.21696
Weintraub D, Burn DJ (2011) Parkinson’s disease: the quintessential psychiatric disorder. Mov Disord 26:1022–1031. https://doi. org/10.1002/mds.23664
Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.